<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>55(12)</volume><submitter>Kim WY</submitter><pubmed_abstract>A recent in vitro study showed that the three compounds of antiviral drugs with different mechanisms of action (amantadine, ribavirin, and oseltamivir) could result in synergistic antiviral activity against influenza virus. However, no clinical studies have evaluated the efficacy and safety of combination antiviral therapy in patients with severe influenza illness. A total of 245 adult patients who were critically ill with confirmed pandemic influenza A/H1N1 2009 (pH1N1) virus infection and were admitted to one of the intensive care units of 28 hospitals in Korea were reviewed. Patients who required ventilator support and received either triple-combination antiviral drug (TCAD) therapy or oseltamivir monotherapy were analyzed. A total of 127 patients were included in our analysis. Among th</pubmed_abstract><journal>Antimicrobial agents and chemotherapy</journal><pagination>5703-9</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC3232815</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Triple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilation.</pubmed_title><pmcid>PMC3232815</pmcid><pubmed_authors>Won Huh J</pubmed_authors><pubmed_authors>Young Suh G</pubmed_authors><pubmed_authors>Lee HB</pubmed_authors><pubmed_authors>Suk Park M</pubmed_authors><pubmed_authors>Kim WY</pubmed_authors><pubmed_authors>Koh Y</pubmed_authors><pubmed_authors>Korean Society of Critical Care Medicine H1N1 Collaborative</pubmed_authors><pubmed_authors>Kim KU</pubmed_authors><pubmed_authors>Huh JW</pubmed_authors><pubmed_authors>Ryu YJ</pubmed_authors><pubmed_authors>Soo Han M</pubmed_authors><pubmed_authors>Kim SH</pubmed_authors><pubmed_authors>Kim SC</pubmed_authors><pubmed_authors>Young Lim C</pubmed_authors><pubmed_authors>Cho JH</pubmed_authors><pubmed_authors>Han MS</pubmed_authors><pubmed_authors>Joo Lee Y</pubmed_authors><pubmed_authors>Lee HK</pubmed_authors><pubmed_authors>Kim MJ</pubmed_authors><pubmed_authors>Kim YS</pubmed_authors><pubmed_authors>Lee MG</pubmed_authors><pubmed_authors>Seong Kim Y</pubmed_authors><pubmed_authors>Bum Park Y</pubmed_authors><pubmed_authors>Sook Kim Y</pubmed_authors><pubmed_authors>Hong SB</pubmed_authors><pubmed_authors>Choi HS</pubmed_authors><pubmed_authors>Young Choi E</pubmed_authors><pubmed_authors>Jeon K</pubmed_authors><pubmed_authors>Kim HR</pubmed_authors><pubmed_authors>Suh GY</pubmed_authors><pubmed_authors>Ahn JJ</pubmed_authors><pubmed_authors>Chon GR</pubmed_authors><pubmed_authors>Lim CM</pubmed_authors><pubmed_authors>Choi SH</pubmed_authors><pubmed_authors>Kwak SH</pubmed_authors><pubmed_authors>Cheol Kim H</pubmed_authors><pubmed_authors>Choi WI</pubmed_authors><pubmed_authors>Ko YG</pubmed_authors><pubmed_authors>Lim J</pubmed_authors><pubmed_authors>Yeol Kim J</pubmed_authors><pubmed_authors>Yun SC</pubmed_authors><pubmed_authors>Gwan Ko Y</pubmed_authors><pubmed_authors>Lee KH</pubmed_authors><pubmed_authors>Ho Lee K</pubmed_authors></additional><is_claimable>false</is_claimable><name>Triple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilation.</name><description>A recent in vitro study showed that the three compounds of antiviral drugs with different mechanisms of action (amantadine, ribavirin, and oseltamivir) could result in synergistic antiviral activity against influenza virus. However, no clinical studies have evaluated the efficacy and safety of combination antiviral therapy in patients with severe influenza illness. A total of 245 adult patients who were critically ill with confirmed pandemic influenza A/H1N1 2009 (pH1N1) virus infection and were admitted to one of the intensive care units of 28 hospitals in Korea were reviewed. Patients who required ventilator support and received either triple-combination antiviral drug (TCAD) therapy or oseltamivir monotherapy were analyzed. A total of 127 patients were included in our analysis. Among th</description><dates><release>2011-01-01T00:00:00Z</release><publication>2011 Dec</publication><modification>2025-04-04T21:13:35.473Z</modification><creation>2019-03-27T00:46:45Z</creation></dates><accession>S-EPMC3232815</accession><cross_references><pubmed>21968371</pubmed><doi>10.1128/AAC.05529-11</doi><doi>10.1128/aac.05529-11</doi></cross_references></HashMap>